SOLANA BEACH, Calif., April 27, 2022 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapeutic platform company enabling brain navigation and delivery, announced today expanding their global license and research agreement with Philips, a global health technology leader, to include access to technology enabling surgical navigation using computed tomography (CT) . The design goal of the ClearPoint Maestro™ brain model for the operating room (OR) is to enable highly accurate procedures with the ClearPoint platform, using CT for live navigation instead of MRI, while maintaining continuity of procedural steps to facilitate training and adoption.
“A visible part of our strategy at ClearPoint is to offer advanced neurosurgery navigation and delivery tools to surgeons around the world, regardless of the area in which the procedure is performed,” commented Joe Burnett, President and CEO of management of ClearPoint Neuro. “Doctors routinely choose the location and technique based on each patient’s needs and disease presentation. There are procedures such as drug delivery and laser ablation that are more commonly performed in MRI because live MRI images provide important information about the success of the procedure. There are other procedures such as biopsy, deep brain stimulation (DBS), and brain-computer interface (BCI) implantation that mostly take place in the operating room today and use computer tools. auxiliary imagery and navigation to get important information along the way. Expanding into the operating room, we can leverage over a decade of experience in neuro-MRI navigation and apply these principles to CT and optical navigation using the ClearPoint platform, partnerships and the same specialized clinical support team. This, in turn, creates centers of excellence and provides scale.
The Philips Brain Model, which is integrated into Maestro, is the result of more than 10 years ago of research aimed at detecting subtle volumetric and shape abnormalities in patients with mild traumatic brain injury. The cover of the Journal of Neurotrauma featured Maestro’s first study. The brain model’s unique methodology combines deformable surfaces with active shape models and machine learning. More importantly, it provides one-time correspondence longitudinally and between patients. Cross-validation on over 1,000 scans demonstrates highly reproducible results with sub-millimeter accuracy and normative values from 560 healthy subjects provide reference ranges for patient-specific assessments.
“Expanding our licensing relationship with Philips to enable access to ClearPoint technology in MRI and CT is key to our planned expansion into the operating room,” continued Mr. Burnett. “By having a common Maestro software platform that can adapt to fusion with MRIs and CT scans, we will have a common software language in the ClearPoint platform that can provide meaningful insights across MRI and OR environments. . Additionally, the workflows will be very similar, so every procedure performed in the OR helps train the physician and surgical team in MRI procedures, and vice versa. These results prove that the more hospitals know about ClearPoint, the more effective future procedures will be. This allows sites to perform multiple procedures on the same day in the same room, increasing the ability to prepare for new indications for DBS, BCI, and drug delivery in the future.
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore the quality of life for patients and their families by enabling therapies for the most complex neurological disorders with pinpoint precision. Applications of the company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuroaspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System is FDA cleared, CE marked, and installed at approximately 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with approximately 40 biologics/pharmaceutical companies and academic centers, providing solutions for the direct delivery of therapeutics to the CNS in preclinical studies and clinical trials worldwide. To date, more than 5,000 cases have been treated and supported by the company’s team of field clinical specialists, who provide support and services to our customers and partners worldwide. For more information, visit www.clearpointneuro.com.
The statements herein regarding the Company’s plans, growth and strategies may include forward-looking statements within the context of federal securities laws. Statements regarding future events, developments and future performance of the Company, as well as management’s expectations, beliefs, plans, estimates or projections regarding the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company’s actual results to differ materially from those expressed or implied by the forward-looking statements. Particular risks and uncertainties include those related to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro navigation system products; the Company’s ability to market, market and achieve broader market acceptance for the Company’s ClearPoint Neuro navigation system products; and the risks inherent in the research and development of new products. More detailed information about these and other factors that could affect the Company’s actual results is described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended 31 December 2021, which has been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2022, which the Company intends to file with the Securities and Exchange Commission. Exchange Commission no later than May 16, 2022.